Antibiotic use and reduced effectiveness of second-line immunotherapy for lung cancer: all the time or just at the start of treatment?

EM van de Garde, LR van Bedaf, Daan Hurkmans, MM Heuvel

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

Research programs

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{b074ceff080449c5b42f6fa1bf6c1e33,

title = "Antibiotic use and reduced effectiveness of second-line immunotherapy for lung cancer: all the time or just at the start of treatment?",

author = "{van de Garde}, EM and {van Bedaf}, LR and Daan Hurkmans and MM Heuvel",

year = "2020",

doi = "10.1016/j.annonc.2020.09.007",

language = "English",

volume = "31",

pages = "1779--1780",

journal = "Annals of Oncology",

issn = "0923-7534",